A University of Edinburgh business-support programme has partnered with Cancer Research UK to help build startup companies focused on tackling cancer. The charity will fund up to ten participants in the second round of the university’s Data-Driven Entrepreneurship (DDE) Venture Builder Incubator, which supports postgraduate students, postdoctoral researchers and academic staff… Read More
Mutations in the ARID1A gene are present in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Scientists at The Wistar Institute discovered that loss of ARID1A function enhances a cellular stress response pathway that promotes survival of cancer cells, which become sensitive… Read More
Scientists from the University of Oxford and the Ludwig Institute for Cancer Research are building on the Oxford-AstraZeneca vaccine for SARS-CoV-2 to develop a vaccine to treat cancer. Researchers have designed a two-dose therapeutic cancer vaccine using Oxford’s viral vector vaccine technology. When tested in mouse tumour models, the… Read More
The Institute of Cancer Research (ICR), London has discovered an investigational drug called NXP800, which cancer patients are set to receive for the first time. It was discovered in a Phase I clinical trial sponsored by an oncology-focused biopharmaceutical company, Nuvectis Pharma. The investigational oral drug inhibits the so-called… Read More
Anti-androgen therapy is commonly used to treat patients with advanced prostate cancer which has spread to the bones, however, the treatment may be fuelling bone cancer spread. Dr Nathalie Bock from QUT Centre for Biomedical Technologies focused her research on bone metastases from breast and prostate cancers. Read More
A new study is trialling whether giving aspirin alongside immunotherapy drug avelumab could improve its effectiveness for people affected by breast cancer. The clinical trial is being funded by the Breast Cancer Now Catalyst Programme, which aims to accelerate progress in breast cancer research through innovation and collaboration. As… Read More
Terumo Blood and Cell Technologies and PhotonPharma have established a memorandum of understanding (MOU) for collaboration to develop Innocell, a novel tumour specific immunotherapy (a therapeutic vaccine)… Read More
The Republic of Belarus Ministry of Health has approved expanding the ongoing clinical trial of CureLab Oncology’s Elenagen, an experimental DNA therapy, to include hormone-resistant breast cancer and hormone-resistant metastatic prostate cancer. The decision to add two more deadly diseases to the ongoing study was based on encouraging preliminary results… Read More
Avacta Group has dosed the first patient in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin and the company’s first therapeutic based on its pre|CISION technology. The pre|CISION platform incorporates a substrate that is specifically cleaved by the protease fibroblast activation protein alpha (FAPa), which is… Read More
Earlier this year, Exscientia announced what was said to be the first AI-designed immuno-oncology drug to enter clinical trials. Lu Rahman talks to CEO Andrew Hopkins about the company’s work and use of AI in drug discovery. LR: How AI has been used in this process and what benefits has… Read More
Following the announcement by Samsung Biologics that it planned to add mRNA vaccine drug substance manufacturing services to its offering, DDW’s Megan Thomas spoke to Seahee Kim about what this means for both business and drug development. MT: As a CDMO, Samsung Biologics can offer both development and manufacturing services. Read More
Listen to this article on the DDW Podcast: At 33, Martyn Hiscox is an inspiration to scientists in oncology research. Principal scientist with Adaptimmune, a UK cell therapy biotech, Lu Rahman uncovers Hiscox’s passion, dedication and the personal reason for developing cell therapy treatments for cancer. Hiscox clearly has immense respect… Read More
eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, has opened a subsidiary, eTheRNA Asia, with offices located in the Sheung Wan area of Hong Kong. The Asia-Pacific region is growing in importance in the global healthcare sector and this new subsidiary will… Read More
RareCan, a new company accelerating research into rare cancers, has appointed Dr Anita Cooper as Non-Executive Director. The appointment is said to strengthen the scientific and pharmaceutical experience of RareCan’s board in support of the company’s planned commercial growth. With over 30 years’ global business experience, Cooper has worked across… Read More
A Mount Sinai study titled Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease describes how a novel therapeutic (108600) combats aggressive chemotherapy-resistant triple-negative breast cancer (TBNC). 108600 targets and inhibits breast cancer stem cells, a subpopulation of cells found within patient triple negative… Read More
In the UK, researchers Professor Andrew Beggs and Professor Gary Middleton from the Institute of Immunology and Immunotherapy and the Institute of Cancer and Genomic Sciences have partnered with Cancer Research UK in a target identification project for the Immuno-oncology Alliance, which translates discovery science into new therapeutics for cancer… Read More
